Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies (NCT05966467)
A Long-Term, Prospective, Observational, Registry of Patients With Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)
🩺 Plain-English Summary (8th-Grade Level)
Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Washington D.C., District of Columbia
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- Clinical Trial Site — Washington D.C., District of Columbia
- Research Site — Boston, Massachusetts
- Clinical Trial Site — Chapel Hill, North Carolina
- Clinical Trial Site — Columbus, Ohio
- Clinical Trial Site — Plano, Texas
- Clinical Trial Site — Milwaukee, Wisconsin
- Clinical Trial Site — Buenos Aires,
- Clinical Trial Site — Buenos Aires,
- Clinical Trial Site — Buenos Aires,
- Clinical Trial Site — Buenos Aires,
- Clinical Trial Site — Burnaby, British Columbia
- Clinical Trial Site — Beijing,
- Clinical Trial Site — Guangzhou,
- Clinical Trial Site — Henan,
- Clinical Trial Site — Shanghai,
- Clinical Trial Site — Sichuan,
- Clinical Trial Site — Wuhan,
- Clinical Trial Site — Dresden,
- Clinical Trial Site — Essen,
- Clinical Trial Site — München,
- Clinical Trial Site — Naples,
- Clinical Trial Site — Fukuoka,
- Clinical Trial Site — Kawasaki,
- Clinical Trial Site — Miyagi,
- Clinical Trial Site — Tokyo,
📞 Contact the Study Coordinator
Phone: (855) 752-2356
Email: clinicaltrials@alexion.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuromyelitis Optica Spectrum Disorder
- Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) — Detroit, Michigan
- Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD — Washington D.C., District of Columbia
- Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy — Aurora, Colorado
- A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) — Denver, Colorado
- Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder — La Jolla, California
Explore by condition: All Neuromyelitis Optica Spectrum Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.